Why would Cervical Cancer Vaccine Might Be Cost-Effective If Administered to Preteens?
A study carried out at the Harvard School of Public Health discovered that cervical cancer vaccine Gardasil might be cost-effective only if administered to females under the age of 12. The findings are important because they show that the US recommendations according to which the vaccine should be administered to women under 26 years of age might imply too greater costs to be worth it.
